Evidence map›Paper›PMID 20447076›Full record

ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2010

Eosinophils in health and disease: the LIAR hypothesis.

J J Lee, E A Jacobsen, M P McGarry, R P Schleimer, N A Lee

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
202citing papers in PubMed, 2 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

202 citing papers in PubMed, 2 syntheses or guidelines pooled it, 327 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Gastrointestinal Eosinophil Responses in a Longitudinal, Randomized Trial of Peanut Oral Immunotherapy.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021
    Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

142 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

J J LeeDepartment of Biochemistry and Molecular Biology, Mayo Clinic Arizona, Scottsdale, 85259, USA. jjlee@mayo.edu <jjlee@mayo.edu>
E A Jacobsen
M P McGarry
R P Schleimer
N A Lee
Mayo Clinic in Arizona · USNorthwestern University · US

Funding

EOSINOPHIL ACTIVITIES IN MURINE MODELS OF LUNG DISEASER01HL065228 · NHLBI · MAYO CLINIC COLL OF MED, MAYO CLINIC AZ · PI JACOBSEN, ELIZABETH A · 2000 to 2017
$6.7M
MOUSE MODELS OF EOSINOPHIL ASSOCIATED LUNG DYSFUNCTIONR01HL058723 · NHLBI · MAYO CLINIC COLL OF MED, MAYO CLINIC AZ · PI LEE, NANCY A. · 1998 to 2013
$4.2M
Role of Epithelium in Immunity, Inflammation and DiseaseR01HL078860 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHLEIMER, ROBERT P · 2006 to 2013
$3.0M
Eosinophil Recruitment and Activation in Solid TumorsR01CA112442 · NCI · MAYO CLINIC ARIZONA · PI LEE, JAMES JOSEPH · 2005 to 2009
$1.6M
Mechanisms of Eosinophil Effector Functions in the LungK26RR019709 · NCRR · MAYO CLINIC ARIZONA · PI LEE, JAMES JOSEPH · 2005 to 2009
$578k
NCI NIH HHS R01 CA112442NCRR NIH HHS K26 RR019709NHLBI NIH HHS R01 HL058723NHLBI NIH HHS R01 HL065228NHLBI NIH HHS R01 HL078860
6 · The paper itself

Abstract

Discussions of eosinophils are often descriptions of end-stage effector cells with destructive capabilities mediated predominantly by released cytotoxic cationic granule proteins. Moreover, eosinophils in the medical literature are invariably associated with the pathologies linked with helminth infections or allergic diseases such as asthma. This has led to an almost fatalist view of eosinophil effector functions and associated therapeutic strategies targeting these cells that would make even William of Ockham proud - eosinophil effector functions have physiological consequences that increase patient morbidity/mortality and 'the only good eosinophils are dead eosinophils'. Unfortunately, the strengths of dogmas are also their greatest weaknesses. Namely, while the repetitive proclamation of dogmatic concepts by authoritative sources (i.e. reviews, meeting proceedings, textbooks, etc.) builds consensus within the medical community and lower the entropies surrounding difficult issues, they often ignore not easily explained details and place diminished importance on alternative hypotheses. The goal of this perspective is twofold: (i) we will review recent observations regarding eosinophils and their activities as well as reinterpret earlier data as part of the synthesis of a new paradigm. In this paradigm, we hypothesize that eosinophils accumulate at unique sites in response to cell turnover or in response to local stem cell activity(ies). We further suggest that this accumulation is part of one or more mechanisms regulating tissue homeostasis. Specifically, instead of immune cells exclusively mediating innate host defence, we suggest that accumulating tissue eosinophils are actually regulators of Local Immunity And/or Remodeling/Repair in both health and disease - the LIAR hypothesis; (ii) we want to be inflammatory (pun intended!) and challenge the currently common perspective of eosinophils as destructive end-stage effector cells. Our hope is to create more questions than we answer and provoke everyone to spend countless hours simply to prove us wrong!

Indexed as

AnimalsAsthmaCytotoxicity, ImmunologicEosinophilsHelminthiasisHematopoiesisHumansMiceNeoplasms

Identifiers

PMID20447076
PMCPMC2951476
OpenAlexW1926391481

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.